Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

University of Wisconsin–Madison–led researchers report lower yet statistically non-significant recurrence of Clostridioides ...

Emapalumab is approved for both adults and pediatric (newborn and older) patients with MAS in Still disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS.

A recently published study revealed significant sex-based disparities in emergency department empiric antibiotic treatment ...

Long-acting lipoglycopeptides are as effective as standard-of-care antibiotics in treating serious bacterial infections in ...

Inappropriate polypharmacy—the excessive or unnecessary use of multiple medications—is a major driver of emergency hospital ...

The FDA has approved Gamifant for the treatment of adult and pediatric patients with HLH/MAS in known or suspected Still disease.

Normally, skin cells take about a month to form and rise to the surface. In people with psoriasis, this process happens in ...

Sobi® (STO: SOBI) today announced that the U.S. Food and Drug Administration (FDA) approved Gamifant® (emapalumab-lzsg) for the treatment of adult and pediatric (newborn and older) patients with ...

Middle ear infection in children is much more common than in adults, in part because of how this part of the ear is designed.

Khatri is funded by a grant from the National Institute on Drug Abuse. Data for this manuscript came from the Institute for ...

Stockholm, Sweden Monday, June 30, 2025, 10:00 Hrs [IST] ...